The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A retrospective analysis assessing effects of cytotoxic versus cytostatic agents on body mass, nutritional parameters, and performance status in patients with exocrine pancreas cancer enrolled in phase I and II trials.
 
John Philip Schwerkoske
No Relationships to Disclose
 
Erkut Borazanci
Consulting or Advisory Role - Biogen (I)
Speakers' Bureau - Biogen (I); Celgene; Genzyme (I); Novartis (I); Teva (I)
Travel, Accommodations, Expenses - Aduro Biotech; Biogen (I)
 
Katy Schroeder
No Relationships to Disclose
 
Lei Zhang
No Relationships to Disclose
 
Gayle S. Jameson
Speakers' Bureau - Celgene
 
Joyce Rosemarie Schaffer
Consulting or Advisory Role - Merck
 
Jeffery A. Nieves
Employment - Astellas Pharma; Celgene
Stock and Other Ownership Interests - Celgene
 
Daniel D. Von Hoff
Employment - McKesson
Stock and Other Ownership Interests - Cell Therapeutics; Insys Therapeutics; McKesson; Medtronic
Honoraria - Celgene; Cerulean Pharma; Clarion Healthcare; Daiichi Sankyo; Genentech; Genzyme; Immunomedics; McKesson; Novartis; OncoMed; Paradigm; Peregrine Pharmaceuticals; Precision Medicine Research Associates, LLC; Puma Biotechnology; Synta; Synta
Consulting or Advisory Role - 3-V Biosciences; AgencyRx; Agenus; Aileron Therapeutics; Arsia Therapeutics; Astrimmune/TYG; Azaya Therapeutics; Biomarin; Bionomics; Bristol-Myers Squibb; Buhl Oncology; Cavion; Cerulean Pharma; CytRx Corporation; Daiichi Sankyo; dalian wanchun biotechnology; DNAtrix; EMD Serono; Esperance Pharmaceuticals; Five Prime Therapeutics; Formula Pharmaceuticals; HealthCare Pharmaceuticals; Heat Biologics; Ignyta; Imaging Endpoints; Immodulon Therapeutics; Inform Genomics; Insys Therapeutics; Invivodata; Lantern Pharma; Lilly; MebioPharm; Medelis; Medical Prognosis Institute; MedTrust Online; MedVax Technologies; Merus; miRNA Therapeutics; Momenta Pharmaceuticals; Nereus Pharmaceuticals; Nucana; Oncolytics; Pain Therapeutics; Pharmacyclics; Pharmatech; Pledpharma; PTC Therapeutics; RadioRx; Reflexion Medical; Research Corporation Technologies; Samumed; Senhwa Biosciences; Superlab Far East; SynDevRx; Teva; Theravance; TNI Biotech; Tolero Pharmaceuticals; Toray Industries; Trovagene; Vaccinex; VidaCare
Research Funding - Abraxis BioScience (Inst); Agios (Inst); Celgene (Inst); Eisai (Inst); Genentech (Inst); Incyte (Inst); Lilly (Inst); Merrimack (Inst); Minneamrita Therapeutics (Inst); Plexxikon (Inst); Taiho Pharmaceutical (Inst)
Patents, Royalties, Other Intellectual Property - 2-aryl-pyridylazoles for the Treatment of Solid Tumors such as Pancreatic Cancer (pending); Intramedullary Catheter; Method of Treating a Tumor (pending); Methods and Kits to Predict Therapeutic Outcome of BTK Inhibitors (pending); Methods of Human Prostate Cancer; Methods, Compounds and Compositions with Genotype Selective Anticancer Activity (pending); Muscle Fatigue Substance Cytokines and Methods of Inhibiting Tumor Growth Therewith (pending); Protein Kinase Inhibitors (pending); Targeting a Protein PRC1 for the Treatment of Pancreatic Cancer (pending); Targeting a Protein Tyrosine Phosphotase-PRL-1 for the Treatment of Pancreatic Cancer (pending); Targeting Ecto-5-Nucleotidase (Cd73) for the Treatment of Pancreatic Cancer; Targeting Ecto-5-Nucleotidase (CD73) for the Treatment of Pancreatic Cancer (pending); Targeting Site-2 Protease (S2P) for the Treatment of Pancreatic Cancer (pending); Use of 5,6-Dihydro-5-Azacytidine in the Treatment of Prostate Cancer
Travel, Accommodations, Expenses - Aileron Therapeutics; Bionomics; Caris Life Sciences; Celgene; Cell Therapeutics; Cerulean Pharma; Cylene; Daiichi Sankyo; DNAtrix; Five Prime Therapeutics; FORMA Therapeutics; Halozyme; Innate Pharma; Lilly; McKesson; Medical Prognosis Institute; miRNA Therapeutics; Novartis; Oncolytics; Partners Healthcare; Quintiles; RadioRx; Senhwa Biosciences; Vaccinex